TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Bifidobacterium Bifidum Supplementation on Morbidity of Very Low Birth Weight Infants
Brief Summary: Probiotic supplementation to preterm infants have been reported to be beneficial in neonatal intensive care unit (NICU). Our pilot study also showed accelerated feeding in preterm infants who received Bifidobacterium bifidum early after birth. In order to evaluate these beneficial effects of Bifidobacterium bifidum, a prospective randomized control study is conducted. The hypothesis of the study is that Bifidobacterium bifidum supplementation to preterm infants improve enteral feeding and growth in very low birth weight infants.


Options:
A: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
C: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Drug: Bifico | Intervention Type: DRUG; Name: Bifico; Assigned to Arm(s): Probiotics

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Bifidobacterium Bifidum Supplementation on Morbidity of Very Low Birth Weight Infants
Brief Summary: Probiotic supplementation to preterm infants have been reported to be beneficial in neonatal intensive care unit (NICU). Our pilot study also showed accelerated feeding in preterm infants who received Bifidobacterium bifidum early after birth. In order to evaluate these beneficial effects of Bifidobacterium bifidum, a prospective randomized control study is conducted. The hypothesis of the study is that Bifidobacterium bifidum supplementation to preterm infants improve enteral feeding and growth in very low birth weight infants.


Options:
A: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
B: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo
C: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Bifidobacterium Bifidum Supplementation on Morbidity of Very Low Birth Weight Infants
Brief Summary: Probiotic supplementation to preterm infants have been reported to be beneficial in neonatal intensive care unit (NICU). Our pilot study also showed accelerated feeding in preterm infants who received Bifidobacterium bifidum early after birth. In order to evaluate these beneficial effects of Bifidobacterium bifidum, a prospective randomized control study is conducted. The hypothesis of the study is that Bifidobacterium bifidum supplementation to preterm infants improve enteral feeding and growth in very low birth weight infants.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
B: Arm Label: group 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: nutrition | Arm Label: group 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: nutrition; Assigned to Arm(s): group 1, group 2
C: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo
D: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Brief Summary: Oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. Tropical enteropathy, which is associated with intestinal inflammation, decreased absorption and increased permeability, may contribute substantially to oral vaccine failure in developing country settings. Other possible causes of oral vaccine underperformance include malnutrition, interference with maternal or breastmilk antibodies, changes in gut microbiota, and genetic susceptibility.

Primary Objective: to determine whether tropical enteropathy impairs the efficacy of oral polio and rotavirus vaccines in children in Bangladesh.

Secondary Objectives: 1) to determine the impact of an IPV (inactivated polio vaccine) boost on the efficacy of OPV (oral polio vaccine) and 2) to determine the efficacy of Rotarix oral rotavirus vaccine to prevent rotavirus diarrhea

The polio and rotavirus randomized clinical trials are embedded as secondary objectives within the exploratory study of tropical enteropathy. The primary and secondary outcome measures are relevant to the randomized clinical trials.


Options:
A: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
D: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Brief Summary: Oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. Tropical enteropathy, which is associated with intestinal inflammation, decreased absorption and increased permeability, may contribute substantially to oral vaccine failure in developing country settings. Other possible causes of oral vaccine underperformance include malnutrition, interference with maternal or breastmilk antibodies, changes in gut microbiota, and genetic susceptibility.

Primary Objective: to determine whether tropical enteropathy impairs the efficacy of oral polio and rotavirus vaccines in children in Bangladesh.

Secondary Objectives: 1) to determine the impact of an IPV (inactivated polio vaccine) boost on the efficacy of OPV (oral polio vaccine) and 2) to determine the efficacy of Rotarix oral rotavirus vaccine to prevent rotavirus diarrhea

The polio and rotavirus randomized clinical trials are embedded as secondary objectives within the exploratory study of tropical enteropathy. The primary and secondary outcome measures are relevant to the randomized clinical trials.


Options:
A: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
D: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment
Brief Summary: This study is to investigate the effect of gastrectomy on remission of type 2 diabetes in patients with gastric cancer and type 2 diabetes, to investigate the mechanism of blood glucose alteration and intestinal hormonal signaling by the reconstruction methods, and to evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after gastrectomy in gastric cancer patients with diabetes.


Options:
A: Arm Label: the group of Roux-en-Y; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-en-Y reconstruction | Arm Label: the group of Uncut Roux-en-Y; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y reconstruction; Assigned to Arm(s): the group of Uncut Roux-en-Y | Intervention Type: PROCEDURE; Name: Roux-en-Y reconstruction; Assigned to Arm(s): the group of Roux-en-Y
B: Arm Label: modified BII+Braun; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modified BII+Braun | Arm Label: traditional BII+Braun; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: modified BII+Braun; Assigned to Arm(s): modified BII+Braun
C: Arm Label: Gastroduodenostomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Gastroduodenostomy | Arm Label: Roux-en Y gastrojejunostomy; Type: EXPERIMENTAL; Interventions: Procedure: Roux-en Y gastrojejunostomy | Intervention Type: PROCEDURE; Name: Roux-en Y gastrojejunostomy; Assigned to Arm(s): Roux-en Y gastrojejunostomy | Intervention Type: PROCEDURE; Name: Gastroduodenostomy; Assigned to Arm(s): Gastroduodenostomy
D: Arm Label: Uncut Roux-en-Y Reconstruction; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y Reconstruction | Arm Label: Billroth II Reconstruction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Billroth II Reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y Reconstruction; Assigned to Arm(s): Uncut Roux-en-Y Reconstruction | Intervention Type: PROCEDURE; Name: Billroth II Reconstruction; Assigned to Arm(s): Billroth II Reconstruction

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuromuscular Training With Whole Body Vibration in Older People: A Randomized Multicentre Clinical Trial With Blinded to Evaluator
Brief Summary: This is a randomized, multicentre, and parallel clinical trial with blinded to evaluator.

The principal hypothesis is that whole-body vibration training plus exercise improves the body balance and prevents falls more than only exercise training in institutionalized older people. The number needed of patients is 160 (80 per group).


Options:
A: Arm Label: Group A, Sunlight; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight | Arm Label: Group B, sunlight and calcium; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight and calcium | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: Other: control | Intervention Type: OTHER; Name: Sunlight; Assigned to Arm(s): Group A, Sunlight | Intervention Type: OTHER; Name: Sunlight and calcium; Assigned to Arm(s): Group B, sunlight and calcium | Intervention Type: OTHER; Name: control; Assigned to Arm(s): Group C
B: Arm Label: Exercise with Whole-body vibration platform; Type: EXPERIMENTAL; Interventions: Device: Exercise with Whole-body vibration platform | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: DEVICE; Name: Exercise with Whole-body vibration platform; Assigned to Arm(s): Exercise with Whole-body vibration platform | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Intervention Type: DEVICE; Name: BedEx Patient Occupancy Monitoring System; Assigned to Arm(s): N/A
D: Arm Label: Whole Body Vibration Group; Type: EXPERIMENTAL; Interventions: Device: Vibrosphère device | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vibrosphère device; Assigned to Arm(s): Whole Body Vibration Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam
Brief Summary: The purpose of this study is to evaluate the safety of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in adult volunteers in Vietnam.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
C: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
D: Arm Label: V260 with staggered EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with staggered EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Arm Label: V260 with concomitant EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with concomitant EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Intervention Type: BIOLOGICAL; Name: V260; Assigned to Arm(s): V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: Placebo to V260; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: DTaP; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam
Brief Summary: The purpose of this study is to evaluate the safety of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in adult volunteers in Vietnam.


Options:
A: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: HRV PCV-free Liq Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Pediarix, Biological: Hiberix, Biological: Prevenar 13 | Arm Label: HRV Lyo Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix, Biological: Pediarix, Biological: Hiberix, Biological: Prevenar 13 | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): HRV Lyo Group, HRV PCV-free Liq Group | Intervention Type: BIOLOGICAL; Name: Pediarix; Assigned to Arm(s): HRV Lyo Group, HRV PCV-free Liq Group | Intervention Type: BIOLOGICAL; Name: Hiberix; Assigned to Arm(s): HRV Lyo Group, HRV PCV-free Liq Group | Intervention Type: BIOLOGICAL; Name: Prevenar 13; Assigned to Arm(s): HRV Lyo Group, HRV PCV-free Liq Group
C: Arm Label: Heat Stable Rotavirus (HSRV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Heat Stable Rotavirus (HSRV) Vaccine | Arm Label: Placebo for Heatstable Rotavirus vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for Heatstable Rotavirus vaccine | Arm Label: Heat Stable Rotavirus Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Heat Stable Rotavirus (HSRV) Vaccine | Arm Label: RotaTeq; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Heat Stable Rotavirus (HSRV) Vaccine; Assigned to Arm(s): Heat Stable Rotavirus (HSRV) Vaccine, Heat Stable Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo for Heatstable Rotavirus vaccine; Assigned to Arm(s): Placebo for Heatstable Rotavirus vaccine | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): RotaTeq
D: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam
Brief Summary: The purpose of this study is to evaluate the safety of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in adult volunteers in Vietnam.


Options:
A: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
B: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
C: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A

Answer: B